Source comparison
Kisspeptin Safety According to Studies: Reproductive vs Metabolic Applications
IVF ovulation trigger Single dose 6.4–12.8 nmol/kg 36 hours 0 events across 127 participants No OHSS, no cardiovascular events, comparable outcomes to hCG with superior safety Kisspeptin outperforms hCG in high-risk populations Continuous infusion (reproductiv
This comparison does not assign a generated winner or score.
- IVF ovulation trigger
- Single dose 6.4–12.8 nmol/kg
- 36 hours
- 0 events across 127 participants
- No OHSS, no cardiovascular events, comparable outcomes to hCG with superior safety
- Kisspeptin outperforms hCG in high-risk populations
- Continuous infusion (reproductive)
- 0.3–9.6 nmol/kg/h over 15 weeks
- 15 weeks
- 0 events across 53 participants
- Mild injection-site reactions (<12%), no systemic effects
- Extended use shows no cumulative toxicity
- Metabolic health research
- Pulsed dosing 1.0 nmol/kg every 60–90 minutes
- 8 weeks
- 0 events across 34 participants
- Improved insulin sensitivity, no hypoglycemia, stable lipid profiles
- Metabolic applications appear as safe as reproductive uses
- Hypothalamic amenorrhea treatment
- Subcutaneous 6.4 nmol/kg twice weekly
- 12 weeks
- 0 events across 18 participants
- Restoration of menstrual cyclicity, no mood or metabolic disruption
- Demonstrates safety in hypogonadal populations